Lv1
20 积分 2024-06-28 加入
MILLING OPERATIONS IN THE PHARMACEUTICAL INDUSTRY
21小时前
已完结
ICH M7 – Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk
30天前
已完结
ICH M7 – Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk
30天前
已关闭
Addressing the Complex Problem of Degradation‐Derived Mutagenic Impurities in Drug Substances and Products
1个月前
已完结
Addressing the Complex Problem of Degradation‐Derived Mutagenic Impurities in Drug Substances and Products
1个月前
已完结
Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals
3个月前
已完结
Genotoxic Threshold Mechanisms and Points of Departure
3个月前
已完结
Compound‐ and Class‐Specific Limits for Common Impurities in Pharmaceuticals
3个月前
已完结
Impurities in Oligonucleotide Drug Substances and Drug Products
5个月前
已完结
Report of the European Medicines Agency Conference on RNA-Based Medicines
9个月前
已完结
皖公网安备34019202002308
